Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals NASDAQ: IONS products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocrine Biosciences' commercial and pipeline strategy. Get Ionis Pharmaceuticals alerts:Sign UpIonis Highlights TRYNGOLZA Opportunity in Severe Hypertriglyceridemia Todd Tushla, vice president of investor relations, said Ionis is preparing for a potential June 30 FDA action date for olezarsen in severe hypertriglyceridemia, or sHTG.

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impac.

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche.

Analyzing the Impact of Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted the 13F filing for the first

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting we.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 A live webcast of these presentations can be accessed on the Investors &a.

Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript